Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJun 19, 2026
DataAggregated Company Financials
Companies65
  • 7D-1.6%
  • 3M5.8%
  • 1Y9.8%
  • YTD-15.4%

Over the last 7 days, the Life Sciences industry has dropped 1.6%, driven by a pullback from Thermo Fisher Scientific of 2.3%. On the other hand 10x Genomics is actually up 21%. Over the past 12 months, the industry was up 9.8%. As for the next few years, earnings are expected to grow by 17% per annum.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 20 Jun 2026US$573.5bUS$150.6bUS$13.7b40.5x41.9x3.8x
Mon, 18 May 2026US$523.0bUS$150.3bUS$14.0b31.2x37.3x3.5x
Wed, 15 Apr 2026US$580.2bUS$147.8bUS$14.1b39x41.2x3.9x
Fri, 13 Mar 2026US$562.3bUS$147.8bUS$14.0b32.9x40.1x3.8x
Sun, 08 Feb 2026US$618.0bUS$147.4bUS$12.9b36.4x48.1x4.2x
Tue, 06 Jan 2026US$689.0bUS$145.8bUS$12.4b36.8x55.7x4.7x
Thu, 04 Dec 2025US$668.5bUS$145.8bUS$12.5b36.5x53.6x4.6x
Sat, 01 Nov 2025US$639.2bUS$145.4bUS$12.2b36x52.6x4.4x
Mon, 29 Sep 2025US$552.3bUS$144.3bUS$14.6b29.4x37.9x3.8x
Wed, 27 Aug 2025US$583.2bUS$144.1bUS$14.5b28.8x40.2x4x
Fri, 25 Jul 2025US$565.9bUS$143.6bUS$8.8b41.6x64.4x3.9x
Sun, 22 Jun 2025US$516.2bUS$142.9bUS$9.2b35.3x56.3x3.6x
Tue, 20 May 2025US$519.6bUS$142.7bUS$9.1b33.4x57.2x3.6x
Thu, 17 Apr 2025US$517.3bUS$142.6bUS$10.0b35x52x3.6x
Sat, 15 Mar 2025US$581.3bUS$143.1bUS$9.8b38.6x59.5x4.1x
Mon, 10 Feb 2025US$658.3bUS$143.1bUS$11.1b38.1x59.3x4.6x
Wed, 08 Jan 2025US$673.1bUS$142.4bUS$10.2b43.9x66x4.7x
Fri, 06 Dec 2024US$671.2bUS$142.4bUS$10.2b43.6x65.7x4.7x
Sun, 03 Nov 2024US$689.4bUS$142.2bUS$8.9b39.1x77.3x4.8x
Tue, 01 Oct 2024US$748.6bUS$141.8bUS$8.5b39x88.1x5.3x
Thu, 29 Aug 2024US$745.7bUS$141.8bUS$8.5b37.7x87.8x5.3x
Sat, 27 Jul 2024US$716.0bUS$141.0bUS$12.5b37.3x57.4x5.1x
Mon, 24 Jun 2024US$694.3bUS$141.3bUS$12.2b38.6x57x4.9x
Wed, 22 May 2024US$739.8bUS$141.5bUS$12.4b38.5x59.5x5.2x
Fri, 19 Apr 2024US$682.0bUS$142.0bUS$12.8b41x53.3x4.8x
Sun, 17 Mar 2024US$742.0bUS$142.1bUS$12.8b43.9x57.8x5.2x
Tue, 13 Feb 2024US$709.9bUS$141.9bUS$12.7b39.2x55.8x5x
Thu, 11 Jan 2024US$692.8bUS$153.9bUS$14.2b36.6x48.9x4.5x
Sat, 09 Dec 2023US$648.8bUS$153.7bUS$14.0b35.2x46.3x4.2x
Mon, 06 Nov 2023US$595.2bUS$153.9bUS$11.0b31.5x54x3.9x
Wed, 04 Oct 2023US$640.4bUS$154.6bUS$11.2b32.3x57.2x4.1x
Fri, 01 Sep 2023US$733.5bUS$154.6bUS$11.2b32.9x65.4x4.7x
Sun, 30 Jul 2023US$734.3bUS$154.7bUS$11.6b31.5x63.2x4.7x
Tue, 27 Jun 2023US$687.9bUS$152.4bUS$12.5b29.3x55x4.5x
Price to Earnings Ratio

55x


Total Market Cap: US$687.9bTotal Earnings: US$12.5bTotal Revenue: US$152.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.2x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 41.9x which is lower than its 3-year average PE of 56.3x.
  • The 3-year average PS ratio of 4.4x is higher than the industry's current PS ratio of 3.8x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 3.1% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.65%
Healthcare-2.14%
Life Sciences-1.63%
Clinical Research and Equipment-1.63%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TXG 10x GenomicsUS$34.7620.5%
+US$750.9m		221.5%PS6.9x
TECH Bio-TechneUS$57.947.3%
+US$616.9m		16.1%PE82.8x
TEM Tempus AIUS$50.846.3%
+US$542.3m		-25.6%PS6.7x
BRKR BrukerUS$57.233.7%
+US$312.1m		48.9%PS2.5x
ILMN IlluminaUS$161.930.6%
+US$145.2m		78.9%PE28.7x

Latest News

TEM
US$50.84
Tempus AI
7D
6.3%
1Y
-25.6%
Analysis Article • 4h

Tempus AI (TEM) Stock Could Be 22.9% Undervalued After ECG AF Validation

Tempus AI (TEM) is back in focus after publishing a multi site validation of its FDA cleared ECG AF software, which predicts one year atrial fibrillation or flutter risk in older adults without prior AF. See our latest analysis for Tempus AI. Tempus AI’s shares have picked up momentum recently, with a 1 month share price return of 10.81% and a 7 day gain of 6.32%. However, the year to date share price return is still down 18.47% and the 1 year total shareholder return has declined 25.57%...
DHR
US$177.17
Danaher
7D
-2.0%
1Y
-8.9%
VRXA
US$4.48
Veraxa Biotech
7D
-77.6%
1Y
-56.8%
ICLR
US$146.00
ICON
7D
-2.6%
1Y
1.7%
TXG
US$34.76
10x Genomics
7D
20.5%
1Y
221.5%
WAT
US$355.44
Waters
7D
-1.2%
1Y
4.7%
Narrative Update • Jun 18

WAT: Battery Safety And Omics Platforms Will Drive Future Stock Upside

Analysts maintained their $460.00 price target on Waters, citing relatively steady assumptions around revenue growth, profit margin, and future P/E, which offset the slightly higher discount rate in their valuation work. What’s in the News for Waters Waters launched the TA Instruments Coin Cell Differential Scanning Calorimeter, combining thermal, evolved gas, and electrochemical analysis in a single experiment to support earlier insights into battery thermal runaway and reduce cell teardown time by over 90% (source: company announcement, 9 June 2026).
BIO
US$282.44
Bio-Rad Laboratories
7D
-3.4%
1Y
21.7%
Narrative Update • Jun 18

BIO: Activist Campaign And Ongoing Buybacks Will Drive Future Share Price

Analysts have kept their $320 price target on Bio-Rad Laboratories steady, citing only modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions that offset each other in their valuation models. What’s in the News for Bio-Rad Laboratories On May 18, 2026, Elliott Investment Management LP disclosed a significant stake in Bio-Rad Laboratories and called for actions aimed at raising the share price, citing what it describes as more than a 70% decline from a peak in late 2021.
TECH
US$57.94
Bio-Techne
7D
7.3%
1Y
16.1%
Narrative Update • Jun 17

TECH: Portfolio Rebrand And Exosome Exit Will Support Future Margin Upside

Analysts have trimmed their Bio-Techne price target slightly from $76.00 to $75.00, reflecting updated views on revenue growth, discount rate and profit margin assumptions, while keeping long term P/E expectations broadly similar. What’s in the News for Bio-Techne Bio-Techne reported 3% organic revenue growth in Q4 fiscal 2025 and maintained profitability in what management described as challenging market conditions, according to its Q4 2025 earnings transcript.
ABCL
US$5.53
AbCellera Biologics
7D
4.9%
1Y
59.4%
Seeking Alpha • Jun 17

AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its Cash

Summary AbCellera, an antibody platform behind two authorized COVID-19 therapies, has rebuilt itself into a clinical-stage biotech and is one quarter away from pivotal Phase 2 data on its first wholly-owned. The deeper story is the platform: an integrated, AI-driven discovery engine that mines millions of immune cells rather than designing molecules from scratch, backed by a decade of proprietary wet lab. With more than $650M in liquidity against a roughly $1.6B market cap, investors are paying little more than cash and effectively getting the platform, the pipeline, and ~100 royalty positions. I initiate my coverage of AbCellera with a “Buy” rating, viewing it as an asymmetric, catalyst-driven bet for investors who can tolerate binary risk. Read the full article on Seeking Alpha
TMO
US$464.61
Thermo Fisher Scientific
7D
-2.3%
1Y
18.4%
Analysis Article • Jun 17

Thermo Fisher Scientific (TMO) Stock Could Be 23% Below Fair Value After Neutral Rating

Piper Sandler’s new Neutral rating on Thermo Fisher Scientific (TMO), alongside a Material Transfer Agreement with Polymer Factory Sweden AB, has drawn fresh attention to how the stock reflects industry conditions and emerging technology partnerships. See our latest analysis for Thermo Fisher Scientific. Thermo Fisher Scientific’s latest share price of $472.63 sits against a mixed backdrop, with the stock down 20.23% on a year to date share price basis but delivering a 21.55% total...
PSNL
US$10.54
Personalis
7D
9.9%
1Y
64.2%
Analysis Article • Jun 16

Personalis (PSNL) Stock Could Be 10% Undervalued After ASCO Cancer Data

Personalis (PSNL) stock is in focus after the company released new clinical data at the 2026 ASCO meeting, highlighting how its NeXT Personal test detects minimal residual disease across six solid tumor types. See our latest analysis for Personalis. The ASCO update comes after a sharp 53.93% 1 month share price return and a 37.50% 3 month share price return. The 1 year total shareholder return of 51.78% and very large 3 year total shareholder return indicate that momentum has been strong...
BRKR
US$57.23
Bruker
7D
3.7%
1Y
48.9%
ILMN
US$161.93
Illumina
7D
0.6%
1Y
78.9%
Narrative Update • Jun 15

ILMN: Future Returns Will Hinge On Clinical Sequencing Momentum And Customer Stickiness

Narrative Update: Illumina The analyst price target underpinning this Illumina narrative has been raised from about $136 to $147, reflecting updated assumptions around customer stickiness, clinical sequencing momentum, and expectations for higher instrument and consumables spending highlighted in recent research. Analyst Commentary Recent research on Illumina reflects a mix of enthusiasm about the company’s position in sequencing markets and some ongoing caution around execution and valuation, with several major firms updating ratings and price targets.
IQV
US$167.77
IQVIA Holdings
7D
-7.3%
1Y
8.5%
Narrative Update • Jun 14

IQV: AI Initiatives And B2B Demand Will Support Earnings Reacceleration

IQVIA Holdings' implied fair value has been trimmed by about $1.65 to roughly $226.95, reflecting analysts' lower price targets around $210 in response to cautious sentiment on life science tools, even as they see early signs of recovery in areas like bioprocessing and quality assurance. Analyst Commentary Recent research points to a mixed setup for IQVIA Holdings, where cautious sentiment on life science tools is bumping up against early signs of recovery in specific end markets.
RGEN
US$132.02
Repligen
7D
1.1%
1Y
11.1%
Narrative Update • Jun 13

RGEN: Bioprocess Recovery And Training Hub Expansion Will Guide Future Performance

Repligen's analyst price target has been reset slightly lower to $142, as analysts factor in a modestly higher discount rate along with still-supportive views on bioprocessing demand and the broader life science tools recovery. Analyst Commentary Recent Street research around Repligen reflects a mixed setup, with several firms trimming price targets and a few others highlighting potential recovery in bioprocessing demand.
A
US$127.06
Agilent Technologies
7D
-1.9%
1Y
10.0%